EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that its common stock traded on the OMX Nordic Exchange in Stockholm has been removed from the observation segment and transferred back to its ordinary position on the Exchange as of today, June, 29, 2009.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that it entered into definitive agreements for the purchase of approximately 12.0 million shares of its common stock at $.80 per share and two-and-one-half-year warrants to purchase up to approximately 4.2 million shares of common stock at an exercise price of $.90 per share exercisable beginning December 19, 2009.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has released new long-term data showing that the use of CepleneŽ when administered in conjunction with low-dose interleukin-2 (IL-2) provides durable protection from leukemia relapse in patients with Acute Myeloid Leukemia (AML), based on a minimum of six years of follow-up. These data will be presented on June 6, 2009 at the European Hematology Associations (EHA) 14th Congress in Berlin, Germany.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has signed an agreement with IDIS, a private, U.K.-based company, to administer a Named Patient Program for CepleneŽ, EpiCepts proprietary therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with Acute Myeloid Leukemia (AML) in first remission. Under this agreement, Ceplene is now available on a named patient basis in Europe in advance of its commercial launch later this year, as well as in the key worldwide markets including South America, Japan, Australia, Israel and Canada.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that its annual meeting of stockholders will be accessible to investors via webcast. The annual meeting will be held on June 2, 2009 at 4:00pm Stockholm time (10:00 am Eastern time) at the Summit Grev Ture Konferens & Event, Grey Turegatan 30 in Stockholm, Sweden.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will present data from its Phase Ia trial of crinobulin at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 29 to June 2, 2009 in Orlando, Florida. Crinobulin is EpiCepts novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced operating and financial results for the three months ended March 31, 2009. For the first quarter of 2009, EpiCepts loss from operations, before other expense and income taxes, was $4.1 million compared with a loss from operations of $6.0 million for the first quarter of 2008.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today the appointment of A. Collier Smyth, M.D., former senior vice president of medical strategy oncology at Bristol-Myers Squibb Company (BMS), to its Board of Directors.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced operating and financial results for the fourth quarter and year ended December 31, 2008.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that the United States Adopted Names Council (USAN) has approved crinobulin as the generic name for EPC2407, the companys novel, small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.